Liquid Biopsy in Biliary Tract Cancer: When Tissue is Not Enough.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 42545218.
- Also identified by DOI 10.1158/1078-0432.CCR-26-2090.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Circulating tumor DNA (ctDNA) profiling detects actionable genomic alterations in advanced biliary tract cancer faster (8 vs 27 days) and more often (90% vs 50%) than tissue, with high concordance. A recent retrospective study establishes clinical validity and a compelling access case for future prospective ctDNA-directed trials.